Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
May 9, 2012
PASADENA, California, May 9, 2012 — Arrowhead Research Corporation (NASDAQ:ARWR) today announced that David Lewis, Ph.D., Vice President Biology and Site Head of its Madison, WI research and development facility presented data at the European Foundation for Clinical Medicine Conference in Basel, Switzerland. Dr. Lewis' presen...
May 8, 2012
PASADENA, Calif. — May 8, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March 31, 2012. Fiscal 2012 Second Quarter and Recent Company Highli...
May 3, 2012
PASADENA, California, May 3, 2012 — Arrowhead Research Corporation (NASDAQ:ARWR) today announced that senior management will present data for its Dynamic PolyConjugateTM (DPC) delivery platform for siRNA delivery including its RNAi therapeutic candidate for the treatment of hepatitis B virus (HBV) at several...
May 1, 2012
PASADENA, California, May 1, 2012 -- Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 second quarter ended March 31, 2012, on Tuesday, May 8, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 1-877-317-6789 (toll free ...
Apr 11, 2012
PASADENA, Calif. — April 11, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced that it has acquired Alvos Therapeutics, Inc. (formerly known as Mercator Therapeutics, Inc.), a privately-held company that licensed a large platform of ...
Mar 7, 2012
PASADENA, Calif. — March 7, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a ...
Mar 5, 2012
PASADENA, Calif. — March 5, 2012 — Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they hav...
Feb 29, 2012
PASADENA, Calif. — February 29, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 8,114,983 B2 entitled, "Compositions and use of ...
Feb 9, 2012
PASADENA, Calif. — February 9, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011. "The first quarter of fiscal 2012 saw transformational change...
Feb 2, 2012
PASADENA, Calif., February 2, 2012 — Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please ...
Page: FirstPrevious ...
21
... NextLast
= add release to Briefcase